Leo Pharma’s tralokinumab meets key endpoints in phase 3 atopic dermatitis trials
LEO Pharma A/S announced that tralokinumab – an investigational, fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and…
Read More...
Read More...
